Q2-osavuosiraportti
33 päivää sitten‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
13 t sitten·Physical presence Invitation to event Date: Tuesday, October 7, 2025 Time: 5:00 PM – 7:00 PM Venue: Auditorium, Tuborg Havnevej 15, st. 2900 Hellerup Market trends in Nordic healthcare stocks - with presentation of BioPorto & Ascelia Pharma Carsten Buhl, BioPorto's new CEO, shares his first reflections after one month in the role and provides insight into the company's strategy, commercial development and future perspectives. The event will conclude with a panel discussion on value creation for shareholders - from clinical innovation to commercialization. – Register in link https://forms.office.com/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGuUKWcGiqM9JlxYrLQwMuApUNkVUWkVEM0ZSVVMyVDRGUEQzREg1VFoxTC4u&route=shorturl
11.9. · Muokattu11.9. · Muokattu2 päivää sitten·Now that the Webinar is over, it will be interesting to hear if it was a success.
8.9.·According to Peter Mørch Eriksen, BioPorto has several patents related to the NGAL test. They expire between 2024 and 2029. The most important patents expire in 2026 and 2028. Would it be problematic for Big Pharma to launch and outcompete BioPorto in the coming years if they think the product is interesting?
8.9.·It is often seen that best-selling products have faced copycat competition upon patent expiration. Maybe one day but weeks or months later.- 5.9.·I wonder what caused the increase!? Was there any news? It's definitely trickling back.9.9.·Just a comment on the above. These are my expectations of CB's sales experience and not a buy or sell recommendation. PME is a researcher and good at raising money for research, and PME's attitude to the NGAL test was that it was so fantastic that it would sell itself, which of course did not happen. CB has experience in selling, and he knows that nothing sells itself, and therefore I also have the expectation of CB that he will agree with Roche that they carry out a campaign with the NGAL test with the relevant customers, to push sales. CB has not put his hand on the stove yet, but he also has his reputation in the industry to think about, because when Bioporto has reached a certain size, he will have to move on. These are my expectations of CB, I have in any case bet some money on it.
5.9.·In the comments below we have Mr. Progression on the field again with predictions about a possible halving of the share price, the likelihood of bankruptcy in 3 years……especially the last one he has mentioned indiscriminately over the past many years….and as everyone can see there has not really been any hold in this message which is more of a personal hope on Progression's part than it is reality. The 3 years have passed many times, but then he just gives it 3 more years. I agree that BioPorto has had a somewhat “bad childhood” with very poor management of the company's money and a lack of professionalism in getting Ngal approved. This is over and the company is definitely in a completely different place today than ever before. The following points help us believe that BioPorto is on the right track, although it may be going slower than many hoped: • Ngal approved for u/21 • Ngal most likely approved for adults in 2027. • New experienced board chairman • New experienced director. • Agreement with Roche on the sale of Ngal • Approved for Roche analysis device. • Approval for more devices on the way. • Possible inclusion in KDIGO guidelines. • Oversubscribed issues. • The largest investors are sticking with it and believe in the case. • Ngal may be used for something other than kidney damage, which will be exciting to follow when approval for adults is in place. BioPorto is so much more visible both in the US and the rest of the world than ever before in connection with trade fairs, workshops, seminars, etc. Could it all have gone a little faster...yes, without a doubt. But to claim that the company is as it has been all along is completely beside the point, and as written, the posts from progression are based on personal hopes, bitterness and the desire for BioPorto to fail/not succeed.🤷♂️5.9.·Topsil, and I'll just add that by just around the corner, I really just meant that it's about a sale that hasn't happened but is coming. That said, there must be a limit to how far out you think that sale can be, now that you don't like this talk about possible new issues.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
33 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 13 t sitten·Physical presence Invitation to event Date: Tuesday, October 7, 2025 Time: 5:00 PM – 7:00 PM Venue: Auditorium, Tuborg Havnevej 15, st. 2900 Hellerup Market trends in Nordic healthcare stocks - with presentation of BioPorto & Ascelia Pharma Carsten Buhl, BioPorto's new CEO, shares his first reflections after one month in the role and provides insight into the company's strategy, commercial development and future perspectives. The event will conclude with a panel discussion on value creation for shareholders - from clinical innovation to commercialization. – Register in link https://forms.office.com/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGuUKWcGiqM9JlxYrLQwMuApUNkVUWkVEM0ZSVVMyVDRGUEQzREg1VFoxTC4u&route=shorturl
- 11.9. · Muokattu11.9. · Muokattu2 päivää sitten·Now that the Webinar is over, it will be interesting to hear if it was a success.
- 8.9.·According to Peter Mørch Eriksen, BioPorto has several patents related to the NGAL test. They expire between 2024 and 2029. The most important patents expire in 2026 and 2028. Would it be problematic for Big Pharma to launch and outcompete BioPorto in the coming years if they think the product is interesting?8.9.·It is often seen that best-selling products have faced copycat competition upon patent expiration. Maybe one day but weeks or months later.
- 5.9.·I wonder what caused the increase!? Was there any news? It's definitely trickling back.9.9.·Just a comment on the above. These are my expectations of CB's sales experience and not a buy or sell recommendation. PME is a researcher and good at raising money for research, and PME's attitude to the NGAL test was that it was so fantastic that it would sell itself, which of course did not happen. CB has experience in selling, and he knows that nothing sells itself, and therefore I also have the expectation of CB that he will agree with Roche that they carry out a campaign with the NGAL test with the relevant customers, to push sales. CB has not put his hand on the stove yet, but he also has his reputation in the industry to think about, because when Bioporto has reached a certain size, he will have to move on. These are my expectations of CB, I have in any case bet some money on it.
- 5.9.·In the comments below we have Mr. Progression on the field again with predictions about a possible halving of the share price, the likelihood of bankruptcy in 3 years……especially the last one he has mentioned indiscriminately over the past many years….and as everyone can see there has not really been any hold in this message which is more of a personal hope on Progression's part than it is reality. The 3 years have passed many times, but then he just gives it 3 more years. I agree that BioPorto has had a somewhat “bad childhood” with very poor management of the company's money and a lack of professionalism in getting Ngal approved. This is over and the company is definitely in a completely different place today than ever before. The following points help us believe that BioPorto is on the right track, although it may be going slower than many hoped: • Ngal approved for u/21 • Ngal most likely approved for adults in 2027. • New experienced board chairman • New experienced director. • Agreement with Roche on the sale of Ngal • Approved for Roche analysis device. • Approval for more devices on the way. • Possible inclusion in KDIGO guidelines. • Oversubscribed issues. • The largest investors are sticking with it and believe in the case. • Ngal may be used for something other than kidney damage, which will be exciting to follow when approval for adults is in place. BioPorto is so much more visible both in the US and the rest of the world than ever before in connection with trade fairs, workshops, seminars, etc. Could it all have gone a little faster...yes, without a doubt. But to claim that the company is as it has been all along is completely beside the point, and as written, the posts from progression are based on personal hopes, bitterness and the desire for BioPorto to fail/not succeed.🤷♂️5.9.·Topsil, and I'll just add that by just around the corner, I really just meant that it's about a sale that hasn't happened but is coming. That said, there must be a limit to how far out you think that sale can be, now that you don't like this talk about possible new issues.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
33 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 13 t sitten·Physical presence Invitation to event Date: Tuesday, October 7, 2025 Time: 5:00 PM – 7:00 PM Venue: Auditorium, Tuborg Havnevej 15, st. 2900 Hellerup Market trends in Nordic healthcare stocks - with presentation of BioPorto & Ascelia Pharma Carsten Buhl, BioPorto's new CEO, shares his first reflections after one month in the role and provides insight into the company's strategy, commercial development and future perspectives. The event will conclude with a panel discussion on value creation for shareholders - from clinical innovation to commercialization. – Register in link https://forms.office.com/pages/responsepage.aspx?id=Xh1dCXi4X0mP_hmzX13BGuUKWcGiqM9JlxYrLQwMuApUNkVUWkVEM0ZSVVMyVDRGUEQzREg1VFoxTC4u&route=shorturl
- 11.9. · Muokattu11.9. · Muokattu2 päivää sitten·Now that the Webinar is over, it will be interesting to hear if it was a success.
- 8.9.·According to Peter Mørch Eriksen, BioPorto has several patents related to the NGAL test. They expire between 2024 and 2029. The most important patents expire in 2026 and 2028. Would it be problematic for Big Pharma to launch and outcompete BioPorto in the coming years if they think the product is interesting?8.9.·It is often seen that best-selling products have faced copycat competition upon patent expiration. Maybe one day but weeks or months later.
- 5.9.·I wonder what caused the increase!? Was there any news? It's definitely trickling back.9.9.·Just a comment on the above. These are my expectations of CB's sales experience and not a buy or sell recommendation. PME is a researcher and good at raising money for research, and PME's attitude to the NGAL test was that it was so fantastic that it would sell itself, which of course did not happen. CB has experience in selling, and he knows that nothing sells itself, and therefore I also have the expectation of CB that he will agree with Roche that they carry out a campaign with the NGAL test with the relevant customers, to push sales. CB has not put his hand on the stove yet, but he also has his reputation in the industry to think about, because when Bioporto has reached a certain size, he will have to move on. These are my expectations of CB, I have in any case bet some money on it.
- 5.9.·In the comments below we have Mr. Progression on the field again with predictions about a possible halving of the share price, the likelihood of bankruptcy in 3 years……especially the last one he has mentioned indiscriminately over the past many years….and as everyone can see there has not really been any hold in this message which is more of a personal hope on Progression's part than it is reality. The 3 years have passed many times, but then he just gives it 3 more years. I agree that BioPorto has had a somewhat “bad childhood” with very poor management of the company's money and a lack of professionalism in getting Ngal approved. This is over and the company is definitely in a completely different place today than ever before. The following points help us believe that BioPorto is on the right track, although it may be going slower than many hoped: • Ngal approved for u/21 • Ngal most likely approved for adults in 2027. • New experienced board chairman • New experienced director. • Agreement with Roche on the sale of Ngal • Approved for Roche analysis device. • Approval for more devices on the way. • Possible inclusion in KDIGO guidelines. • Oversubscribed issues. • The largest investors are sticking with it and believe in the case. • Ngal may be used for something other than kidney damage, which will be exciting to follow when approval for adults is in place. BioPorto is so much more visible both in the US and the rest of the world than ever before in connection with trade fairs, workshops, seminars, etc. Could it all have gone a little faster...yes, without a doubt. But to claim that the company is as it has been all along is completely beside the point, and as written, the posts from progression are based on personal hopes, bitterness and the desire for BioPorto to fail/not succeed.🤷♂️5.9.·Topsil, and I'll just add that by just around the corner, I really just meant that it's about a sale that hasn't happened but is coming. That said, there must be a limit to how far out you think that sale can be, now that you don't like this talk about possible new issues.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt